Sell-Side Analysts Mostly Express Undying Love For Valeant As Regulators Express Doubts

As the majority of sell-side analysis rushed in to defend Valeant Pharmaceuticals yesterday and early this morning, there is one point of consistency in a key component of the case that is being overlooked. The odd question of how the sales cycle worked and how a relatively small pharmacy was able to rack up such debt with Valeant has remained on the sidelines. All the positive research notes come as Valeant stock is down near 18 percent in early morning trade, and Pershing Square losing . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email and we will get back to you as quick as humanly possible

Saved Articles

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers